Q32 Bio Inc.
Q32 Bio is a clinical stage biotechnology company dedicated to developing biologic therapeutics that restore immune homeostasis in autoimmune and inflammatory diseases. Their mission is to transform the lives of patients by targeting key regulators of the immune system, including the IL-7/TSLP receptor pathways and the complement system. They focus on innovative therapies such as anti-IL-7Rα antibodies and tissue-targeted complement inhibitors, with multiple programs in clinical development, including Phase 2 trials for conditions like alopecia areata, atopic dermatitis, and complement-mediated diseases.
Industries
Nr. of Employees
small (1-50)
Q32 Bio Inc.
Patents
Methods of treating complement mediated diseases with fusion protein constructs comprising anti-C3d antibody and a complement modulator
US-11879008-B2
View DetailsFusion protein constructs comprising anti-C3d antibody and CR1 polypeptide
US-11053305-B2
View Details
Methods of treating complement mediated diseases with fusion protein constructs comprising anti-C3d antibody and a complement modulator
US-11879008-B2
View DetailsFusion protein constructs comprising anti-C3d antibody and CR1 polypeptide
US-11053305-B2
View DetailsProducts
Monoclonal antibody therapeutic targeting IL-7Rα (clinical-stage)
A fully human antagonistic monoclonal antibody directed at IL-7Rα designed to block IL-7 and TSLP-mediated signaling to re-regulate adaptive immune function; advanced through Phase 1 and into Phase 2 clinical trials for autoimmune dermatologic indications.
Tissue-targeted complement inhibitor fusion protein (first-in-human completed)
A fusion protein that links a tissue-deposited complement fragment–binding antibody domain to complement regulatory protein fragments to inhibit alternative pathway complement activity in diseased tissues while avoiding systemic complement blockade; completed Phase 1 and planned Phase 2 renal and vasculitis studies.
Monoclonal antibody therapeutic targeting IL-7Rα (clinical-stage)
A fully human antagonistic monoclonal antibody directed at IL-7Rα designed to block IL-7 and TSLP-mediated signaling to re-regulate adaptive immune function; advanced through Phase 1 and into Phase 2 clinical trials for autoimmune dermatologic indications.
Tissue-targeted complement inhibitor fusion protein (first-in-human completed)
A fusion protein that links a tissue-deposited complement fragment–binding antibody domain to complement regulatory protein fragments to inhibit alternative pathway complement activity in diseased tissues while avoiding systemic complement blockade; completed Phase 1 and planned Phase 2 renal and vasculitis studies.
Services
Operational management and execution of clinical development activities under collaboration or funding agreements with pharmaceutical partners; includes conduct of Phase 1 and Phase 2 studies and biomarker-enabled trials.
Strategic planning and operational oversight of CMC activities to advance clinical-stage therapeutics, including manufacturing strategy, process development and coordination of CMC deliverables for regulatory filings.
Operational management and execution of clinical development activities under collaboration or funding agreements with pharmaceutical partners; includes conduct of Phase 1 and Phase 2 studies and biomarker-enabled trials.
Strategic planning and operational oversight of CMC activities to advance clinical-stage therapeutics, including manufacturing strategy, process development and coordination of CMC deliverables for regulatory filings.
Expertise Areas
- Clinical trial management
- Antibody therapeutics development
- Tissue-targeted complement therapeutics
- Preclinical in vivo pharmacology
Key Technologies
- Monoclonal antibody therapeutics
- Fusion protein therapeutics
- C3d-mediated tissue targeting
- Tissue-targeted complement inhibition
News & Updates
Q32 Bio now wholly owns development and commercialization rights to Bempikibart, currently evaluated in Phase 2 trials for atopic dermatitis and alopecia areata, after re-acquiring rights from Amgen following Amgen's acquisition of Horizon Therapeutics.
Q32 Bio announced a $60 million Series B financing to support the advancement of ADX-914 and ADX-097, with plans to initiate Phase 2 trials for these programs. The financing was co-led by OrbiMed Advisors and Acorn Bioventures.
Jodie Morrison was appointed as Board Member and Acting CEO, succeeding Michael Broxson, bringing extensive leadership experience in biotech.
Jodie Morrison appointed as CEO to lead the company into later-stage clinical trials and pipeline expansion.
Q32 Bio and Horizon Therapeutics entered into a collaboration to develop ADX-914 for autoimmune diseases, with Horizon funding Phase 2 trials and holding an option to acquire the program.
Q32 Bio announced dosing in a Phase 1 clinical trial evaluating ADX-097, a tissue-targeted complement inhibitor, with plans for Phase 2 trials in renal diseases and AAV.
Q32 Bio now wholly owns development and commercialization rights to Bempikibart, currently evaluated in Phase 2 trials for atopic dermatitis and alopecia areata, after re-acquiring rights from Amgen following Amgen's acquisition of Horizon Therapeutics.
Q32 Bio announced a $60 million Series B financing to support the advancement of ADX-914 and ADX-097, with plans to initiate Phase 2 trials for these programs. The financing was co-led by OrbiMed Advisors and Acorn Bioventures.
Jodie Morrison was appointed as Board Member and Acting CEO, succeeding Michael Broxson, bringing extensive leadership experience in biotech.
Jodie Morrison appointed as CEO to lead the company into later-stage clinical trials and pipeline expansion.
Q32 Bio and Horizon Therapeutics entered into a collaboration to develop ADX-914 for autoimmune diseases, with Horizon funding Phase 2 trials and holding an option to acquire the program.
Q32 Bio announced dosing in a Phase 1 clinical trial evaluating ADX-097, a tissue-targeted complement inhibitor, with plans for Phase 2 trials in renal diseases and AAV.